Stroke Prevention

1. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database.

Author
Rowan SB; Bailey DN; Bublitz CE; Anderson RJ;
Institution
Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262, USA.
Journal
J Am Coll Cardiol. 2007 Apr 10;49(14):1561-5. Epub 2007 Mar 26.
Abstract URL
Click here to view abstract

2. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.

Author
Sick PB; Schuler G; Hauptmann KE; Grube E; Yakubov S; Turi ZG; Mishkel G; Almany S; Holmes DR;
Institution
Krankenhaus der Barmherzigen Bruder, Regensburg, Germany. peter.sick@barmherzige-regensburg.de
Journal
J Am Coll Cardiol. 2007 Apr 3;49(13):1490-5. Epub 2007 Mar 21.
Abstract URL
Click here to view abstract

3. Combining aspirin with oral anticoagulant therapy: is this a safe and effective practice in patients with atrial fibrillation?

Author
Gorelick PB;
Institution
Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, Illinois 60612, USA. pgorelic@uic.edu
Journal
Stroke. 2007 May;38(5):1652-4. Epub 2007 Mar 29.

4. Antithrombotic treatment and stroke severity in patients with atrial fibrillation.

Author
Bornstein NM; Auriel E;
Institution
NM Bornstein is a Professor of Neurology and E Auriel is a Resident at the Department of Neurology and Stroke Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Journal
Nat Clin Pract Neurol. 2007 May;3(5):252-3. Epub 2007 Mar 6.

5. Anticoagulation in atrial fibrillation: a contemporary viewpoint.

Author
Wyse DG;
Institution
Libin Cardiovascular Institute of Alberta, University of Calgary, and Calgary Health Region, Calgary, Alberta, Canada. dgwyse@ucalgary.ca
Journal
Heart Rhythm. 2007 Mar;4(3 Suppl):S34-9. Epub 2006 Dec 6.
Abstract URL
Click here to view abstract

6. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.

Author
White HD; Gruber M; Feyzi J; Kaatz S; Tse HF; Husted S; Albers GW;
Institution
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand. harveyw@adhb.govt.nz
Journal
Arch Intern Med. 2007 Feb 12;167(3):239-45.
Abstract URL
Click here to view abstract

7. Newly detected atrial fibrillation and compliance with antithrombotic guidelines.

Author
Glazer NL; Dublin S; Smith NL; French B; Jackson LA; Hrachovec JB; Siscovick DS; Psaty BM; Heckbert SR;
Institution
Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, 1730 Minor Avenue, Seattle, WA 98101, USA. nlg@u.washington.edu
Journal
Arch Intern Med. 2007 Feb 12;167(3):246-52.
Abstract URL
Click here to view abstract

8. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.

Author
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW;
Institution
Mercy Stroke Center, Sacramento, CA, USA. akins@surewest.net
Journal
Stroke. 2007 Mar;38(3):874-80. Epub 2007 Jan 25.
Abstract URL
Click here to view abstract